What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?
Kim M. Olthoff, Alejandro Forner, Stefan Hübscher, John Fung – 7 June 2011
Hepatocyte cytotoxicity is facilitated by asialoglycoprotein receptor
Clifford S. Guy, Sherri L. Rankin, Tomasz I. Michalak – 7 June 2011 – It has been recently identified that hepatocytes can act as cytotoxic effectors and can kill contacted cells by way of CD95 ligand–CD95 and perforin‐dependent pathways. However, it remained unknown whether hepatocyte‐mediated cell killing is indiscriminant or is directed toward targets with particular cell surface characteristics, as well as whether hepatocytes have the capacity to directly eliminate contacted lymphocytes.
Reply:
Sophie Lotersztajn, Fatima Teixeira‐Clerc, Vanessa Deveaux, Sylvie Manin, Ariane Mallat – 7 June 2011
Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature
Isabel Campos‐Varela, Lluís Castells, Cristina Dopazo, Mercedes Pérez‐Lafuente, Helena Allende, Oscar Len, Lluís Llopart, Victor Vargas, Ramón Charco – 7 June 2011 – Sinusoidal obstruction syndrome (SOS) is a rare, life‐threatening clinical syndrome resulting from sinusoidal congestion, and it is characterized by hepatomegaly, ascites, weight gain, and jaundice. The frequency of this condition after liver transplantation (LT) is low, but when SOS is severe and refractory to medical therapy, the ultimate solution is retransplantation.
Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: A systematic review
Evangelos Cholongitas, John Goulis, Evangelos Akriviadis, Geore V. Papatheodoridis – 7 June 2011 – A combination of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues (NUCs) is currently recommended as prophylaxis against the recurrence of hepatitis B virus (HBV) after liver transplantation (LT), but the optimal protocol is a matter of controversy. The aim of this study was the identification of factors associated with post‐LT HBV recurrence in patients receiving HBIG and NUCs.
Should we use living donor grafts for patients with hepatocellular carcinoma? ethical considerations
Elizabeth A. Pomfret, J. Peter A. Lodge, Federico G. Villamil, Mark Siegler – 7 June 2011
Patients' expectations and success criteria for liver transplantation
James R. Rodrigue, Douglas W. Hanto, Michael P. Curry – 7 June 2011 – Patient‐reported outcomes are important to consider when the relative success of liver transplantation (LT) is being evaluated. Our primary objective was to examine the expectations for LT and the criteria for its success across 4 domains of functioning (pain, fatigue, emotional distress, and interference with daily activities) from the perspective of patients who were wait‐listed for LT.
Region‐specific challenges for minimizing endemic donor‐transmitted infections
Sherif Beniameen Mossad – 7 June 2011
2010 International consensus conference on liver transplantation for hepatocellular carcinoma: Texts of experts
Mickael Lesurtel, Pierre‐Alain Clavien – 7 June 2011
Social barriers to listing for adult liver transplantation: Their prevalence and association with program characteristics
Anna Flattau, Manhal Olaywi, Paul J. Gaglio, Paula Marcus, Paul Meissner, Emily B. L. Dorfman, John F. Reinus – 7 June 2011 – Social barriers to effective medical care are mandated to be routinely assessed as part of an evaluation for liver transplantation. This study explores how frequently liver transplant programs encounter these barriers in patients undergoing an evaluation and whether programs with higher proportions of Medicaid patients, historically disadvantaged minority patients, and rural patients encounter social barriers more frequently.